{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.526.2.1382","meta":{"versionId":"18","lastUpdated":"2017-09-26T01:00:05.000-04:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"PCPI Author"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2022-12-15"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2017-09-26"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1382","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.3.526.2.1382"}],"version":"20170926","name":"IntoleranceToAntineoplasticTherapy","title":"Intolerance to Antineoplastic Therapy","status":"active","experimental":false,"date":"2017-09-26T01:00:05-04:00","publisher":"PCPI Steward","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development)","compose":{"include":[{"system":"http://snomed.info/sct","concept":[{"code":"292196008","display":"Antineoplastic adverse reaction (disorder)"},{"code":"292234002","display":"Fluorouracil adverse reaction (disorder)"}]}]},"expansion":{"identifier":"urn:uuid:f7515ca6-e232-4b72-87a6-f28abf77602f","timestamp":"2023-12-11T02:45:00-05:00","total":2,"contains":[{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20230901","code":"292196008","display":"Antineoplastic adverse reaction (disorder)"},{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20230901","code":"292234002","display":"Fluorouracil adverse reaction (disorder)"}]}}